news - International Biopharmaceutical Industry

Current Edition

news

Nektar’s Sole Skeptic Warns of Parallels to Biggest Biotech Flop

A long-time skeptic of Nektar Therapeutics on Wall Street remains cautious after Monday’s 42 percent plunge, the worst performance for an S&P 500 Index member in ...

8 June 2018 news Biotech | flop

Continue Reading →

news

Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors

Orchard Therapeutics, a leading commercial stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies,...

8 June 2018 news Announces | appointments

Continue Reading →

news

Philips, SAM open regional oncology centre in Singapore

First phase of Singapore’s Advanced Medicine Imaging Center provides accurate and timely diagnosis of cancer, plus an education center for medical training and scie...

8 June 2018 news centre | oncology

Continue Reading →

news

Vetter Strikes Out on New Pathways to Further Develop the Injection Process

Vetter kicks off its Open Innovation Challenge: Dr. Claudia Roth, Vice President Innovation Management, welcomes the ...

8 June 2018 news develop | injection

Continue Reading →

news

ASCO18: 3 unanswered questions from oncology’s largest conference

Each year, the ASCO annual meeting serves as a forum for some of the most important clinical studies in oncology, giving physicians important insights into how best...

8 June 2018 news ASCO | conference

Continue Reading →

news

BIO18: Pfizer (sort of) inches back to neuro; Building ties with FDA

BIO hits its goal Three days into the BIO International convention, the industry group touted breaking the G...

8 June 2018 news BIO | BIO18

Continue Reading →

news

NICE Annual Conference 2018

Date: Tuesday 26 June, 2018 Location: 303 Deansgate Manchester M3 4LQ The NICE annual conference returns on 26 June 2018 in Manchester and it showcases the latest d...

1 June 2018 news 2018 | annual

Continue Reading →

news

Johnson & Johnson has the most bucks for biopharma M&A, Astellas the easiest target: analyst

The $62 billion Takeda-Shire deal surprised everyone—and worries some—as Takeda is borrowing an enormous $31 billion to help pay for the purchase. Does it refresh the...

1 June 2018 news Astellas | biopharma

Continue Reading →

news

vTv Therapeutics shares soar on licensing tie-up with Chinese group Newsoara Biopharma

Newsoara will develop vTv Therapeutics' HPP737 as a new treatment for chronic obstructive pulmonary disease VTv Therape...

1 June 2018 news chinese | group

Continue Reading →

news

Half of orphan drug sales to come from cancer, Evaluate finds

Oncology already sits as the top-selling therapeutic area on the orphan drug market, but a new report predicts it to account for even more — half, in fact — of sa...

1 June 2018 news cancer | Drug

Continue Reading →